Stephan Grabbe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5680662/publications.pdf

Version: 2024-02-01

212 papers

18,428 citations

54 h-index 130 g-index

225 all docs 225 docs citations

times ranked

225

21031 citing authors

#	Article	IF	CITATIONS
1	LAight® Therapy Significantly Enhances Treatment Efficacy of 16 Weeks of Topical Clindamycin Solution in Hurley I and II Hidradenitis Suppurativa: Results from Period A of RELIEVE, a Multicenter Randomized, Controlled Trial. Dermatology, 2022, 238, 476-486.	0.9	12
2	Efficacy and Toxicity of Classical Immunosuppressants, Retinoids and Biologics in Hidradenitis Suppurativa. Journal of Clinical Medicine, 2022, 11, 670.	1.0	2
3	Biological medication in atopic dermatitis. Expert Opinion on Biological Therapy, 2022, , 1-7.	1.4	5
4	S1â€guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS). JDDG - Journal of the German Society of Dermatology, 2022, 20, 235-243.	0.4	8
5	Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors. ACS Nano, 2022, 16, 4426-4443.	7.3	33
6	Rosacea management: A comprehensive review. Journal of Cosmetic Dermatology, 2022, 21, 1895-1904.	0.8	24
7	Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?. Cancers, 2022, 14, 1710.	1.7	13
8	Poliosis Is Associated with Response to Checkpoint-Inhibitor Therapy: A Case Report of Two Patients with Multifocal Metastatic Melanoma. Immuno, 2022, 2, 307-316.	0.6	2
9	Pathogenesis, Immunology and Management of Dermatophytosis. Journal of Fungi (Basel, Switzerland), 2022, 8, 39.	1.5	12
10	Surgical Treatment in Hidradenitis Suppurativa. Journal of Clinical Medicine, 2022, 11, 2311.	1.0	10
11	The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study. Cancers, 2022, 14, 2082.	1.7	9
12	Inhibitors of the Actin-Bundling Protein Fascin-1 Developed for Tumor Therapy Attenuate the T-Cell Stimulatory Properties of Dendritic Cells. Cancers, 2022, 14, 2738.	1.7	2
13	Enrichment Methods for Murine Liver Non-Parenchymal Cells Differentially Affect Their Immunophenotype and Responsiveness towards Stimulation. International Journal of Molecular Sciences, 2022, 23, 6543.	1.8	4
14	Itch in Hidradenitis Suppurativa/Acne Inversa: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 3813.	1.0	4
15	\hat{I}^2 2 Integrins on Dendritic Cells Modulate Cytokine Signaling and Inflammation-Associated Gene Expression, and Are Required for Induction of Autoimmune Encephalomyelitis. Cells, 2022, 11, 2188.	1.8	4
16	Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF). Journal of Dermatological Treatment, 2021, 32, 530-537.	1.1	20
17	Green tea extract as a successful topical treatment option in children with perianal condylomata. JDDG - Journal of the German Society of Dermatology, 2021, 19, 113-115.	0.4	O
18	The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment. Cancers, 2021, 13, 210.	1.7	86

#	Article	IF	CITATIONS
19	Simvastatin in vitiligo: an update with recent review of the literature. International Journal of Dermatology, 2021, 60, e390-e396.	0.5	2
20	Complement-Opsonized Nano-Carriers Are Bound by Dendritic Cells (DC) via Complement Receptor (CR)3, and by B Cell Subpopulations via CR-1/2, and Affect the Activation of DC and B-1 Cells. International Journal of Molecular Sciences, 2021, 22, 2869.	1.8	12
21	Hair Transplantation Surgery Versus Other Modalities of Treatment in Androgenetic Alopecia: A Narrative Review. Cosmetics, 2021, 8, 25.	1.5	5
22	Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanomaâ€"A Retrospective Multicenter ADOReg Study. Cancers, 2021, 13, 2312.	1.7	11
23	Idiopathic guttate hypomelanosis: Presentation and Management. Journal of Cosmetic and Laser Therapy, 2021, 23, 8-15.	0.3	1
24	Chronic Kidney Disease-Associated Pruritus. Toxins, 2021, 13, 527.	1.5	31
25	Chronic venous insufficiency, cardiovascular disease, and mortality: a population study. European Heart Journal, 2021, 42, 4157-4165.	1.0	37
26	Density of Conjugated Antibody Determines the Extent of Fc Receptor Dependent Capture of Nanoparticles by Liver Sinusoidal Endothelial Cells. ACS Nano, 2021, 15, 15191-15209.	7.3	32
27	Regulatory T Cells Prevent Neutrophilic Infiltration of Skin during Contact Hypersensitivity Reactions by Strengthening theÂEndothelial Barrier. Journal of Investigative Dermatology, 2021, 141, 2006-2017.	0.3	9
28	Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapyâ€"Paradoxical ERK Activation and Beyond. International Journal of Molecular Sciences, 2021, 22, 9890.	1.8	14
29	Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma. Cancer Medicine, 2021, 10, 1562-1575.	1.3	16
30	Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors—A Retrospective, Real-World Cohort Study. Cancers, 2021, 13, 5103.	1.7	25
31	S1â€Guideline Cutaneous Angiosarcomas – Update 2021. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1801-1812.	0.4	2
32	Merkel Cell Carcinoma: From Pathobiology to Clinical Management. Biology, 2021, 10, 1293.	1.3	8
33	Machine Learning and Its Application in Skin Cancer. International Journal of Environmental Research and Public Health, 2021, 18, 13409.	1.2	56
34	Effective treatment of disseminated superficial actinic porokeratosis with chemical peels – customary treatment for a rare disease. Journal of Dermatological Treatment, 2020, 31, 744-748.	1.1	2
35	Using immuno-PET imaging to monitor kinetics of T cell-mediated inflammation and treatment efficiency in a humanized mouse model for GvHD. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1314-1325.	3.3	19
36	Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature. Dermatologic Therapy, 2020, 33, e13215.	0.8	21

#	Article	IF	CITATIONS
37	Complications of botulinum toxin and fillers: A narrative review. Journal of Cosmetic Dermatology, 2020, 19, 570-573.	0.8	34
38	Transient Multivalent Nanobody Targeting to CD206-Expressing Cells via PH-Degradable Nanogels. Cells, 2020, 9, 2222.	1.8	11
39	Increased risk of angiosarcoma secondary to cancer radiotherapy: Case series and review of the treatment options. Dermatologic Therapy, 2020, 33, e13234.	0.8	4
40	An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature, 2020, 585, 107-112.	13.7	526
41	Systemic immunosuppression in times of COVIDâ€19: Do we need to rethink our standards?. JDDG - Journal of the German Society of Dermatology, 2020, 18, 810-813.	0.4	10
42	Platelet-Derived GARP Induces Peripheral Regulatory T Cells—Potential Impact on T Cell Suppression in Patients with Melanoma-Associated Thrombocytosis. Cancers, 2020, 12, 3653.	1.7	14
43	Role of Hypoxia and the Adenosine System in Immune Evasion and Prognosis of Patients with Brain Metastases of Melanoma: A Multiplex Whole Slide Immunofluorescence Study. Cancers, 2020, 12, 3753.	1.7	11
44	A brief synopsis on scalp melanoma. Dermatologic Therapy, 2020, 33, e13795.	0.8	6
45	Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: A narrative review. Dermatologic Therapy, 2020, 33, e13800.	0.8	6
46	Efficacy of 595- and 1319-nm pulsed dye laser in the treatment of acne vulgaris: a narrative review. Journal of Cosmetic and Laser Therapy, 2020, 22, 111-114.	0.3	5
47	Acanthosis nigricans: A review. Journal of Cosmetic Dermatology, 2020, 19, 1857-1865.	0.8	47
48	Update in minimally invasive periorbital rejuvenation with a focus on plateletâ€rich plasma: A narrative review. Journal of Cosmetic Dermatology, 2020, 19, 1057-1062.	0.8	15
49	Low-level laser therapy and narrative review of other treatment modalities in androgenetic alopecia. Lasers in Medical Science, 2020, 35, 1239-1244.	1.0	10
50	Merkel cell carcinomaâ€derived Erysipelas carcinomatosum. Dermatologic Therapy, 2020, 33, e13287.	0.8	1
51	Selective RAR agonists for acne vulgaris: A narrative review. Journal of Cosmetic Dermatology, 2020, 19, 1278-1283.	0.8	14
52	î²2 Integrins—Multi-Functional Leukocyte Receptors in Health and Disease. International Journal of Molecular Sciences, 2020, 21, 1402.	1.8	71
53	Emerging drugs for the treatment of vitiligo. Expert Opinion on Emerging Drugs, 2020, 25, 7-24.	1.0	44
54	Review of biologics in allergic contact dermatitis. Contact Dermatitis, 2020, 83, 179-181.	0.8	15

#	Article	IF	CITATIONS
55	Solidarity and transparency against the $\langle scp \rangle COVID \langle scp \rangle$ $\hat{a} \in 19$ pandemic. Dermatologic Therapy, 2020, 33, e13359.	0.8	30
56	5â€Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. Dermatologic Therapy, 2020, 33, e13379.	0.8	31
57	Safety of the current drug treatments for vitiligo. Expert Opinion on Drug Safety, 2020, 19, 499-511.	1.0	14
58	Complication of Soft Tissue Fillers: Prevention and Management Review. Journal of Drugs in Dermatology, 2020, 19, 829-832.	0.4	12
59	RhoA as a Key Regulator of Innate and Adaptive Immunity. Cells, 2019, 8, 733.	1.8	130
60	Platelets Aggregate With Neutrophils and Promote Skin Pathology in Psoriasis. Frontiers in Immunology, 2019, 10, 1867.	2.2	29
61	S2k‣eitlinie Basalzellkarzinom der Haut – Teil 1: Epidemiologie, Genetik und Diagnostik. JDDG - Journal of the German Society of Dermatology, 2019, 17, 94-104.	0.4	23
62	S1 guidelines for dermatofibrosarcoma protuberans (DFSP) – update 2018. JDDG - Journal of the German Society of Dermatology, 2019, 17, 663-668.	0.4	18
63	S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – update 2018. JDDG - Journal of the German Society of Dermatology, 2019, 17, 562-576.	0.4	27
64	Sodium chloride is an ionic checkpoint for human T $<$ sub $>$ H $<$ /sub $>$ 2 cells and shapes the atopic skin microenvironment. Science Translational Medicine, 2019, 11, .	5.8	66
65	CD11b Regulates Fungal Outgrowth but Not Neutrophil Recruitment in a Mouse Model of Invasive Pulmonary Aspergillosis. Frontiers in Immunology, 2019, 10, 123.	2.2	28
66	S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Followâ€up. JDDG - Journal of the German Society of Dermatology, 2019, 17, 214-230.	0.4	57
67	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nature Medicine, 2019, 25, 1916-1927.	15.2	541
68	lgEâ€specific immunoadsorption: New treatment option for severe refractory atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1190-1193.	2.7	5
69	Protein corona–mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses. Journal of Allergy and Clinical Immunology, 2018, 142, 1558-1570.	1.5	60
70	Sentinel lymph node biopsy in malignant melanoma of the head and neck. Journal of Cranio-Maxillo-Facial Surgery, 2018, 46, 1027-1031.	0.7	11
71	Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. British Journal of Cancer, 2018, 118, 785-792.	2.9	34
72	S2k Guidelines – Cutaneous Lymphomas Update 2016 – Part 2: Treatment and Followâ€up (ICD10 C82 ―C JDDG - Journal of the German Society of Dermatology, 2018, 16, 112-122.	86).4	29

#	Article	IF	Citations
73	BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells. Oncotarget, 2018, 9, 28294-28308.	0.8	36
74	Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters. Strahlentherapie Und Onkologie, 2018, 194, 1144-1151.	1.0	29
75	Delivering all in one: Antigen-nanocapsule loaded with dual adjuvant yields superadditive effects by DC-directed T cell stimulation. Journal of Controlled Release, 2018, 289, 23-34.	4.8	33
76	Interleukin-1 Beta—A Friend or Foe in Malignancies?. International Journal of Molecular Sciences, 2018, 19, 2155.	1.8	268
77	The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery. Frontiers in Immunology, 2018, 9, 1760.	2.2	63
78	Friend virus limits adaptive cellular immune responses by imprinting a maturation-resistant and T helper type 2-biased immunophenotype in dendritic cells. PLoS ONE, 2018, 13, e0192541.	1.1	3
79	Abstract CT156: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma. Cancer Research, 2018, 78, CT156-CT156.	0.4	10
80	CD11b Regulates Fungal Outgrowth but Not Neutrophil Recruitment in a Mouse Model of Invasive Pulmonary Aspergillosis. Blood, 2018, 132, 3690-3690.	0.6	0
81	Acquired symmetric asymptomatic lesions at the inner corners of the eyes. JDDG - Journal of the German Society of Dermatology, 2017, 15, 342-344.	0.4	0
82	New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Research, 2017, 27, 155-158.	0.6	116
83	Pembrolizumabâ€induced lichen planus pemphigoides in a patient with metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2017, 15, 742-745.	0.4	20
84	PeptoSomes for Vaccination: Combining Antigen and Adjuvant in Polypept(o)ideâ€Based Polymersomes. Macromolecular Bioscience, 2017, 17, 1700061.	2.1	18
85	S2k Guidelines – Cutaneous Lymphomas Update 2016 – Part 1: Classification and Diagnosis (ICD10 C82 â€;	TjETQq1	1 0.784314 12
86	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 2017, 547, 222-226.	13.7	1,806
87	Role of Protein Kinase C and Nox2-Derived Reactive Oxygen Species Formation in the Activation and Maturation of Dendritic Cells by Phorbol Ester and Lipopolysaccharide. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-12.	1.9	15
88	Shifting cancer care towards Multidisciplinarity: the cancer center certification program of the German cancer society. BMC Cancer, 2017, 17, 850.	1.1	68
89	Abstract CT034: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent melanoma immunotherapy. Cancer Research, 2017, 77, CT034-CT034.	0.4	4
90	Two brothers with confluent and reticulated papillomatosis. JDDG - Journal of the German Society of Dermatology, 2016, 14, 1303-1305.	0.4	2

#	Article	IF	Citations
91	Past, present and future of immunology in Mainz. Cellular Immunology, 2016, 308, 1-6.	1.4	O
92	Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma. Nanomedicine, 2016, 11, 2723-2734.	1.7	82
93	Toll like receptor mediated immune stimulation can be visualized in vivo by [18 F]FDG-PET. Nuclear Medicine and Biology, 2016, 43, 651-660.	0.3	12
94	Vaccination with trifunctional nanoparticles that address CD8+dendritic cells inhibits growth of established melanoma. Nanomedicine, 2016, 11, 2647-2662.	1.7	19
95	Nanoparticles and the immune system: challenges and opportunities. Nanomedicine, 2016, 11, 2621-2624.	1.7	30
96	Targeting cells of the immune system: mannosylated HPMA–LMA block-copolymer micelles for targeting of dendritic cells. Nanomedicine, 2016, 11, 2679-2697.	1.7	22
97	Immune checkpoint inhibitors: a milestone in the treatment of melanoma. JDDG - Journal of the German Society of Dermatology, 2016, 14, 685-695.	0.4	15
98	Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature, 2016, 534, 396-401.	13.7	1,243
99	Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities. Future Oncology, 2016, 12, 95-106.	1.1	15
100	A key role of GARP in the immune suppressive tumor microenvironment. Oncotarget, 2016, 7, 42996-43009.	0.8	26
101	Abstract CT022: IVAC® MUTANOME - A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma. , 2016, , .		0
102	Abstract A004: Systemic RNA vaccines: Connecting effective cancer immunotherapy with antiviral defense mechanisms. , 2016 , , .		0
103	Multifaceted Contributions of Epidermal Langerhans Cells to Cutaneous Carcinogenesis. Journal of Investigative Dermatology, 2015, 135, 1218-1220.	0.3	5
104	<i>In vitro</i> and <i>in vivo</i> imaging of initial B-T-cell interactions in the setting of B-cell based cancer immunotherapy. Oncolmmunology, 2015, 4, e1038684.	2.1	16
105	Prurigo nodularis as index symptom of (nonâ∈Hodgkin) lymphoma: ultrasound as a helpful diagnostic tool in dermatological disorders of unknown origin. International Journal of Dermatology, 2015, 54, 462-464.	0.5	11
106	Abstract CT202: IVAC MUTANOME: Individualized vaccines for the treatment of cancer. Cancer Research, 2015, 75, CT202-CT202.	0.4	4
107	Increased frequencies of <scp>CD</scp> 11b ⁺ <scp>CD</scp> 33 ⁺ <scp>CD</scp> 14 ⁺ <scp>HLA<td>scp>â€<s 1.4</s </td><td>cp35R</td></scp>	scp>â€ <s 1.4</s 	cp35R
108	Selective Uptake of Cylindrical Poly(2â€Oxazoline) Brushâ€AntiDEC205 Antibodyâ€OVA Antigen Conjugates into DECâ€Positive Dendritic Cells and Subsequent Tâ€Cell Activation. Chemistry - A European Journal, 2014, 20, 12405-12410.	1.7	40

#	Article	IF	CITATIONS
109	Dendritic Cell Motility and T Cell Activation Requires Regulation of Rho-Cofilin Signaling by the Rho-GTPase Activating Protein Myosin IXb. Journal of Immunology, 2014, 192, 3559-3568.	0.4	46
110	Toward Anticancer Immunotherapeutics: Wellâ€Defined Polymer–Antibody Conjugates for Selective Dendritic Cell Targeting. Macromolecular Bioscience, 2014, 14, 1444-1457.	2.1	22
111	Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma – simultaneous occurrence of pyoderma gangrenosum and colitis. European Journal of Dermatology, 2014, 24, 268-269.	0.3	23
112	Update of Immune Events in the Murine Contact Hypersensitivity Model: Toward the Understanding of Allergic Contact Dermatitis. Journal of Investigative Dermatology, 2013, 133, 303-315.	0.3	303
113	The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells. Cancer Immunology, Immunotherapy, 2013, 62, 1315-1326.	2.0	21
114	Solution Properties and Potential Biological Applications of Zwitterionic Poly ($\hat{l}\mu$ -N-methacryloyl-l-lysine). Macromolecules, 2013, 46, 8519-8527.	2.2	27
115	CD40L contributes to angiotensin II-induced pro-thrombotic state, vascular inflammation, oxidative stress and endothelial dysfunction. Basic Research in Cardiology, 2013, 108, 386.	2.5	55
116	Angiotensin Il–Induced Vascular Dysfunction Depends on Interferon-γ–Driven Immune Cell Recruitment and Mutual Activation of Monocytes and NK-Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1313-1319.	1,1	131
117	Brief S2k guidelines – Merkel cell carcinoma. JDDG - Journal of the German Society of Dermatology, 2013, 11, 29-36.	0.4	20
118	Brief S2k guidelines – Cutaneous squamous cell carcinoma. JDDG - Journal of the German Society of Dermatology, 2013, 11, 37-45.	0.4	50
119	Serum S100B Levels Correlate with Clinical Benefit in a Metastatic Melanoma Patient Treated by CTLA-4 Blockade: A Case Report. Onkologie, 2013, 36, 578-581.	1.1	5
120	Screening for Distress in Routine Oncological Careâ€"A Survey in 520 Melanoma Patients. PLoS ONE, 2013, 8, e66800.	1.1	46
121	The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. PLoS ONE, 2013, 8, e53745.	1.1	414
122	A Trifunctional Dextran-Based Nanovaccine Targets and Activates Murine Dendritic Cells, and Induces Potent Cellular and Humoral Immune Responses In Vivo. PLoS ONE, 2013, 8, e80904.	1.1	23
123	Repression of Cyclic Adenosine Monophosphate Upregulation Disarms and Expands Human Regulatory T Cells. Journal of Immunology, 2012, 188, 1091-1097.	0.4	40
124	Adaptive Immune Response to Model Antigens Is Impaired in Murine Leukocyte-Adhesion Deficiency-1 Revealing Elevated Activation ThresholdsIn Vivo. Clinical and Developmental Immunology, 2012, 2012, 1-11.	3.3	5
125	Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovascular Research, 2012, 96, 140-149.	1.8	152
126	Allergen-induced IgE-dependent gut inflammation in a human PBMC–engrafted murine model of allergy. Journal of Allergy and Clinical Immunology, 2012, 129, 1126-1135.	1.5	35

#	Article	IF	CITATIONS
127	Enhanced production of CCL18 by tolerogenic dendritic cells is associated with inhibition of allergic airway reactivity. Journal of Allergy and Clinical Immunology, 2012, 130, 1384-1393.	1.5	25
128	CD40 Ligand Deficiency Attenuates Angiotensin II Induced Oxidative Stress and Endothelial Dysfunction in a Murine Model of Arterial Hypertension. Biophysical Journal, 2012, 102, 66a.	0.2	0
129	Differential gene expression analysis identifies murine Cacnb3 as strongly upregulated in distinct dendritic cell populations upon stimulation. Gene, 2011, 472, 18-27.	1.0	15
130	Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-α2b: patients' and doctors' views. European Journal of Dermatology, 2011, 21, 976-984.	0.3	7
131	Clinical Efficacy of Blue Light Full Body Irradiation as Treatment Option for Severe Atopic Dermatitis. PLoS ONE, 2011, 6, e20566.	1.1	66
132	Melanocytic nevi. JDDG - Journal of the German Society of Dermatology, 2011, 9, 723-734.	0.4	16
133	Interferon-α Abrogates Tolerance Induction by Human Tolerogenic Dendritic Cells. PLoS ONE, 2011, 6, e22763.	1.1	11
134	Lysozyme M–Positive Monocytes Mediate Angiotensin II–Induced Arterial Hypertension and Vascular Dysfunction. Circulation, 2011, 124, 1370-1381.	1.6	422
135	LFA-1 activity state on dendritic cells regulates contact duration with T cells and promotes T-cell priming. Blood, 2010, 116, 1885-1894.	0.6	46
136	Mutated cylindromatosis gene affects the functional state of dendritic cells. European Journal of Immunology, 2010, 40, 2848-2857.	1.6	11
137	Dendritic cells lentivirally engineered to overexpress interleukinâ€10 inhibit contact hypersensitivity responses, despite their partial activation induced by transductionâ€associated physical stress. Journal of Gene Medicine, 2010, 12, 231-243.	1.4	18
138	Sentinel Lymph Node Excision and PET-CT in the Initial Stage of Malignant Melanoma. Dermatologic Surgery, 2010, 36, 439-445.	0.4	32
139	Effects of glycation of the model food allergen ovalbumin on antigen uptake and presentation by human dendritic cells. Immunology, 2010, 129, 437-445.	2.0	102
140	Release of IL-12 by dendritic cells activated by TLR ligation is dependent on MyD88 signaling, whereas TRIF signaling is indispensable for TLR synergy. Journal of Leukocyte Biology, 2010, 88, 189-199.	1.5	85
141	LFA-1 Contributes to Signal I of T-Cell Activation and to the Production of Th1 Cytokines. Journal of Investigative Dermatology, 2010, 130, 1005-1012.	0.3	60
142	The RNA binding protein tristetraprolin influences the activation state of murine dendritic cells. Molecular Immunology, 2010, 47, 1161-1170.	1.0	13
143	Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma. Journal of Clinical Oncology, 2009, 27, 2823-2830.	0.8	517
144	Prospective Randomized Multicenter Adjuvant Dermatologic Cooperative Oncology Group Trial of Low-Dose Interferon Alfa-2b With or Without a Modified High-Dose Interferon Alfa-2b Induction Phase in Patients With Lymph Node–Negative Melanoma. Journal of Clinical Oncology, 2009, 27, 3496-3502.	0.8	33

#	Article	IF	Citations
145	A novel plasmid DNA electroporation method allows transfection of murine DC. Journal of Immunological Methods, 2009, 343, 13-20.	0.6	5
146	Uptake and presentation of exogenous antigen and presentation of endogenously produced antigen by skin dendritic cells represent equivalent pathways for the priming of cellular immune responses following biolistic DNA immunization. Immunology, 2009, 128, e193-205.	2.0	27
147	l̂² ₂ Integrin deficiency yields unconventional doubleâ€negative T cells distinct from mature classical natural killer T cells in mice. Immunology, 2009, 128, 271-286.	2.0	10
148	Dendritic cell activation by combined exposure to antiâ€CD40 plus interleukin (IL)â€12 and ILâ€18 efficiently stimulates antiâ€tumor immunity. Experimental Dermatology, 2009, 18, 78-87.	1.4	19
149	Myeloid dendritic cell: From sentinel of immunity to key player of peripheral tolerance?. Human Immunology, 2009, 70, 289-293.	1.2	74
150	Giant pyogenic granuloma. Cmaj, 2008, 178, 25-26.	0.9	5
151	Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas. European Journal of Dermatology, 2008, 18, 29-35.	0.3	10
152	IL-10 Controls Ultraviolet-Induced Carcinogenesis in Mice. Journal of Immunology, 2007, 179, 365-371.	0.4	136
153	Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation. Blood, 2007, 109, 661-669.	0.6	113
154	Friend retrovirus infection of myeloid dendritic cells impairs maturation, prolongs contact to $na\tilde{A}$ ve T cells, and favors expansion of regulatory T cells. Blood, 2007, 110, 3949-3958.	0.6	44
155	Patch test results in patients with scalp dermatitis: analysis of data of the Information Network of Departments of Dermatology. Contact Dermatitis, 2007, 56, 87-93.	0.8	48
156	SWAP-70 associates transiently with macropinosomes. European Journal of Cell Biology, 2007, 86, 13-24.	1.6	19
157	Influence of pH on wound-healing: a new perspective for wound-therapy?. Archives of Dermatological Research, 2007, 298, 413-420.	1.1	769
158	Phase II Trial of a Toll-Like Receptor 9–Activating Oligonucleotide in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2006, 24, 5716-5724.	0.8	197
159	Effect of pimecrolimus vs. corticosteroids on murine bone marrow-derived dendritic cell differentiation, maturation and function. Experimental Dermatology, 2006, 15, 43-50.	1.4	17
160	Immune response modifiers? mode of action. Experimental Dermatology, 2006, 15, 331-341.	1.4	100
161	Angiokeratoma circumscriptum arranged in a systematized band-like pattern suggesting mosaicism. Journal of Dermatology, 2006, 33, 489-491.	0.6	15
162	Telangiectasias on the neck as a presenting cutaneous sign of Fabry disease. Journal of Dermatology, 2006, 33, 652-654.	0.6	4

#	Article	IF	CITATIONS
163	Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nature Medicine, 2006, 12, 1372-1379.	15.2	378
164	Migration of immature mouse DC across resting endothelium is mediated by ICAM-2 but independent of \hat{l}^22 -integrins and murine DC-SIGN homologues. European Journal of Immunology, 2006, 36, 2781-2794.	1.6	22
165	Structure and duration of contact between dendritic cells and T cells are controlled by T cell activation state. European Journal of Immunology, 2006, 36, 3105-3117.	1.6	57
166	Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood, 2005, 106, 2424-2432.	0.6	102
167	IL-12 Breaks Dinitrothiocyanobenzene (DNTB)-Mediated Tolerance and Converts the Tolerogen DNTB into an Immunogen. Journal of Immunology, 2005, 175, 5866-5874.	0.4	14
168	An Important Role of CD80/CD86-CTLA-4 Signaling during Photocarcinogenesis in Mice. Journal of Immunology, 2005, 174, 5298-5305.	0.4	46
169	Senescent BALB/c Mice Are Able To Develop Resistance to Leishmania major Infection. Infection and Immunity, 2004, 72, 5106-5114.	1.0	36
170	Radiotherapy of Benign Diseasesâ€"Scleredema Adultorum Buschke. Strahlentherapie Und Onkologie, 2004, 180, 811-814.	1.0	21
171	DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends in Immunology, 2004, 25, 659-664.	2.9	72
172	A spectrum of biophysical interaction modes between T cells and different antigen-presenting cells during priming in 3-D collagen and in vivo. Blood, 2004, 104, 2801-2809.	0.6	119
173	Monocyte and macrophage functions in M-CSF-deficientop/opmice during experimental leishmaniasis. Journal of Leukocyte Biology, 2003, 73, 564-573.	1.5	23
174	CD4+ T Cell-Associated Pathophysiology Critically Depends on CD18 Gene Dose Effects in a Murine Model of Psoriasis. Journal of Immunology, 2003, 171, 5697-5706.	0.4	53
175	Significant Risk of a Second Melanoma in Patients with a History of Melanoma but No Further Predisposing Factors. Dermatology, 2003, 206, 76-77.	0.9	22
176	Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1. Blood, 2002, 99, 946-956.	0.6	75
177	Role of integrins in T cell trafficking. Experimental Dermatology, 2002, 11, 479-480.	1.4	0
178	\hat{l}^22 integrins are required for skin homing of primed T cells but not for priming naive T cells. Journal of Clinical Investigation, 2002, 109, 183-192.	3.9	66
179	\hat{l}^22 integrins are required for skin homing of primed T cells but not for priming naive T cells. Journal of Clinical Investigation, 2002, 109, 183-192.	3.9	37
180	IL-12 Prevents the Inhibitory Effects of <i>cis</i> -Urocanic Acid on Tumor Antigen Presentation by Langerhans Cells: Implications for Photocarcinogenesis. Journal of Immunology, 2001, 167, 6232-6238.	0.4	76

#	Article	IF	CITATIONS
181	Dendritic cells and tumor immunity. Seminars in Immunology, 2001, 13, 291-302.	2.7	58
182	Dendritic Cells in Cancer Immunotherapy. Critical Reviews in Immunology, 2001, 21, 13.	1.0	31
183	Two-step negative enrichment of CD4+ and CD8+ T cells from murine spleen via nylon wool adherence and an optimized antibody cocktail. Journal of Immunological Methods, 2001, 258, 55-63.	0.6	58
184	Overexpression of Cd40 Ligand in Murine Epidermis Results in Chronic Skin Inflammation and Systemic Autoimmunity. Journal of Experimental Medicine, 2001, 194, 615-628.	4.2	158
185	Mycophenolate Mofetil Impairs the Maturation and Function of Murine Dendritic Cells. Journal of Immunology, 2000, 165, 2374-2381.	0.4	178
186	In experimental leishmaniasis deficiency of CD18 results in parasite dissemination associated with altered macrophage functions and incomplete Th1 cell response. European Journal of Immunology, 2000, 30, 2729-2740.	1.6	40
187	Dendritic cells: multi-lineal and multi-functional. Trends in Immunology, 2000, 21, 431-433.	7.5	107
188	Evidence for Functional Relevance of CTLA-4 in Ultraviolet-Radiation-Induced Tolerance. Journal of Immunology, 2000, 165, 1824-1831.	0.4	152
189	Antigen Presentation in Extracellular Matrix. Immunity, 2000, 13, 323-332.	6.6	408
190	Interaction of Dendritic Cells with Skin Endothelium: A New Perspective on Immunosurveillance. Journal of Experimental Medicine, 1999, 189, 627-636.	4.2	172
191	Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells. Nature Medicine, 1998, 4, 328-332.	15.2	2,689
192	Interleukin 12 Breaks Ultraviolet Light Induced Immunosuppression by Affecting CD8+ Rather Than CD4+T Cells. Journal of Investigative Dermatology, 1998, 110, 272-276.	0.3	28
193	Differential Regulation of Epidermal Cell Tumor-Antigen Presentation by IL-1Î \pm and IL-1Î 2 . Journal of Investigative Dermatology, 1998, 111, 609-615.	0.3	12
194	Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Trends in Immunology, 1998, 19, 37-44.	7.5	500
195	High-dose UVA1 therapy for atopic dermatitis: Results of a multicenter trial. Journal of the American Academy of Dermatology, 1998, 38, 589-593.	0.6	205
196	Topically applied pentoxifylline has no effect on allergic patch responses. Journal of the American Academy of Dermatology, 1998, 39, 1017-1021.	0.6	12
197	UV-induced T suppressor cells act by inducing cell death of antigen presenting cells via the Fas/Fas-ligand system. Journal of Dermatological Science, 1998, 16, S19.	1.0	0
198	Spontaneous Skin Ulceration and Defective T Cell Function in CD18 Null Mice. Journal of Experimental Medicine, 1998, 188, 119-131.	4.2	352

#	Article	IF	CITATIONS
199	CD14 is Expressed by Subsets of Murine Dendritic Cells and Upregulated by Lipopolysaccharide. Advances in Experimental Medicine and Biology, 1997, 417, 145-159.	0.8	27
200	The Role of $\hat{l}\pm$ -Melanocyte-Stimulating Hormone in Cutaneous Biology. Journal of Investigative Dermatology Symposium Proceedings, 1997, 2, 87-93.	0.8	118
201	Interaction of murine dendritic cells with collagen up-regulates allostimulatory capacity, surface expression of heat stable antigen, and release of cytokines. Journal of Leukocyte Biology, 1996, 60, 465-472.	1.5	28
202	Interleukin-12 Prevents Ultraviolet B-Induced Local Immunosuppression and Overcomes UVB-Induced Tolerance. Journal of Investigative Dermatology, 1996, 106, 1187-1191.	0.3	125
203	Reply from Grabbe and Granstein. Trends in Immunology, 1995, 16, 547-548.	7.5	1
204	Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?. Trends in Immunology, 1995, 16, 117-121.	7.5	251
205	Mechanisms of Ultraviolet Radiation Carcinogenesis. Chemical Immunology and Allergy, 1994, 58, 291-313.	1.7	15
206	Interleukin $1\hat{l}\pm$ but Not Transforming Growth Factor \hat{l}^2 Inhibits Tumor Antigen Presentation by Epidermal Antigen-Presenting Cells. Journal of Investigative Dermatology, 1994, 102, 67-73.	0.3	35
207	In Vivo Effects of Interleukin-10 on Contact Hypersensitivity and Delayed-Type Hypersensitivity Reactions. Journal of Investigative Dermatology, 1994, 103, 211-216.	0.3	141
208	Interferon- \hat{l}^3 inhibits tumor antigen presentation by epidermal antigen-presenting cells. Journal of Leukocyte Biology, 1994, 55, 695-701.	1.5	25
209	Tumor antigen presentation by epidermal antigen-presenting cells in the mouse: modulation by granulocyte-macrophage colony-stimulating factor, tumor necrosis factor \hat{l}_{\pm} , and ultraviolet radiation. Journal of Leukocyte Biology, 1992, 52, 209-217.	1.5	54
210	Molecular cloning of a G protein-coupled receptor that is highly expressed in lymphocytes and proliferative areas of developing brain. Molecular and Cellular Neurosciences, 1992, 3, 206-214.	1.0	8
211	Cyclosporin Increases Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF) Activity and Gene Expression in Murine Keratinocytes. Journal of Investigative Dermatology, 1992, 98, 274-278.	0.3	11
212	Effects of Immunomodulatory Cytokines on the Presentation of Tumor-Associated Antigens by Epidermal Langerhans Cells. Journal of Investigative Dermatology, 1992, 99, S66-S68.	0.3	36